Skip to main content

The CancerConnect Anal Cancer Newsletter

Stay Current With Anal Cancer Treatment Advances & Connect with Others

CancerConnect Anal Cancer Newsletter

CancerConnect publishes daily cancer news, original articles and "tips" on the management of Anal Cancer. These are available in our monthly Anal Cancer newsletter.

Stay Current - Connect With Other Anal Cancer Patients

Join The CancerConnect Community: Connect with others and receive regular updates

or

Scroll to Continue

Recommended Articles

Image placeholder title

Zenocutuzumab - the first approved systemic therapy for patients with NRG1 fusion–positive NSCLC or pancreatic adenocarcinoma.

Zenocutuzumab targeted therapy approved for treatment of pancreatic ductal adenocarcinoma and non-small cell lung cancer with NRG1 fusions.

small cell lung cancer

Immunotherapy After Chemoradiotherapy Promising in Limited-Stage Small Cell Lung Cancer

Adjuvant therapy with Imfinzi (durvalumab) significantly improved survival outcomes for patients with limited-stage SCLC

Gut microbiome

Breakthrough in Understanding Tamoxifen's Effectiveness in Breast Cancer: Gut Bacteria Play a Crucial Role

Since tamoxifen is taken orally and travels through the digestive system, variations in patient responses may be connected to the gut microbiome—the trillions of bacteria in our intestines that differ significantly from one person to another.

Sign up for the Anal Cancer Newsletter Here